An FDA panel voted overwhelmingly in favor of new, stricter labelling for drospirenone-containing birth control pills, including Yaz and Yasmin. The new labelling directive comes after recent data suggests these types of birth control pills carry a significant increased risk of blood clots. The panel spent over nine hours discussing research related to the blood clot risk of drospirenone. Ultimately, the panel found that current labelling was inadequate and that new labels should make patients and physicians more aware of the potential life-threatening side-effects.
Full story here: http://nydn.us/rNxuWN